Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349209 | 1.00 | SRR (0.50) | SRRPPARGPPARACTRB1ACE | |
| SCHEMBL5349207 | 1.00 | SRR (0.50) | SRRPPARGPPARACTRB1ACE | |
| SCHEMBL2053 | 0.86 | SRR (0.53) | SRRPPARGPPARACTRB1ACE | |
| SCHEMBL1486321 | 0.86 | SRR (0.62) | SRRPPARGPPARAACEALPI | |
| SCHEMBL1486323 | 0.86 | SRR (0.62) | SRRPPARGPPARAACEALPI | |
| SCHEMBL2626716 | 0.86 | SRR (0.62) | SRRPPARGPPARAACEALPI | |
| SCHEMBL27769333 | 0.83 | ACE (0.51) | SRRPPARGPPARAACE | |
| SCHEMBL29156974 | 0.83 | SRR (0.54) | SRRPPARGPPARACTRB1ACE | |
| SCHEMBL3712940 | 0.83 | PPARG (0.51) | SRRPPARGPPARACTRB1ACE | |
| SCHEMBL11436318 | 0.80 | MMP8 (0.54) | SRRPPARGPPARAACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
| US-6998416-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | SRR 2945/4885PPARG 2310/4885PPARA 2458/4885 |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | SRR 2945/4885PPARG 2310/4885PPARA 2458/4885 |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | SRR 2945/4885PPARG 2310/4885PPARA 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.